247 related articles for article (PubMed ID: 34112200)
1. Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy.
Lu D; Wang Y; Zhang T; Wang F; Li K; Zhou S; Zhu H; Yang Z; Liu Z
J Nanobiotechnology; 2021 Jun; 19(1):175. PubMed ID: 34112200
[TBL] [Abstract][Full Text] [Related]
2. In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy.
Kim W; Yoon HY; Lim S; Stayton PS; Kim IS; Kim K; Kwon IC
J Control Release; 2021 Jan; 329():223-236. PubMed ID: 33290794
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
[TBL] [Abstract][Full Text] [Related]
4. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
[TBL] [Abstract][Full Text] [Related]
5. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
[TBL] [Abstract][Full Text] [Related]
6. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.
Jiang H; Shin DH; Yi Y; Fan X; Gumin J; He J; Gillard AG; Lang FF; Gomez-Manzano C; Fueyo J
Cancer Res Commun; 2023 Jun; 3(6):1118-1131. PubMed ID: 37379361
[TBL] [Abstract][Full Text] [Related]
8. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
9. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.
Hornung RL; Longo DL; Bowersox OC; Kwak LW
J Natl Cancer Inst; 1995 Sep; 87(17):1289-96. PubMed ID: 7544833
[TBL] [Abstract][Full Text] [Related]
11. Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.
Haque M; Song J; Fino K; Sandhu P; Wang Y; Ni B; Fang D; Song J
Cell Transplant; 2016; 25(5):811-27. PubMed ID: 26777320
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
13. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
[TBL] [Abstract][Full Text] [Related]
14. Monitoring CD8a
Kristensen LK; Christensen C; Alfsen MZ; Cold S; Nielsen CH; Kjaer A
Mol Imaging Biol; 2020 Aug; 22(4):1021-1030. PubMed ID: 32086762
[TBL] [Abstract][Full Text] [Related]
15. T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging.
Agger R; Petersen MS; Petersen CC; Hansen SB; Stødkilde-Jørgensen H; Skands U; Blankenstein T; Andersen TE; Hulgaard EF; Jørgensen JT; Marqversen J; Gundersen HJ; Hokland ME
J Immunother; 2007 Jan; 30(1):29-39. PubMed ID: 17198081
[TBL] [Abstract][Full Text] [Related]
16. Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.
Li A; Wu Y; Linnoila J; Pulli B; Wang C; Zeller M; Ali M; Lewandrowski GK; Li J; Tricot B; Keliher E; Wojtkiewicz GR; Fulci G; Feng X; Tannous BA; Yao Z; Chen JW
Cancer Immunol Immunother; 2016 Dec; 65(12):1545-1554. PubMed ID: 27722909
[TBL] [Abstract][Full Text] [Related]
17. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
18. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
19. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
